Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. (Nasdaq: CDNA) is a precision medicine company in the medical laboratories industry that focuses on transplant patients and caregivers. The company describes itself as “The Transplant Company” and emphasizes genomics‑based information, non‑invasive molecular testing, and digital health technologies for heart, kidney, and lung transplantation. This news page brings together company announcements and disclosures that illustrate how CareDx develops and commercializes transplant‑focused diagnostics and solutions.
Readers can expect news related to financial results, where CareDx reports revenue across testing services, product revenue, and patient and digital solutions revenue. The company issues press releases on quarterly and preliminary annual performance, highlighting trends in testing services volume and segment‑level revenue. These updates provide context on how its transplant‑focused offerings are used in clinical practice.
CareDx also publishes clinical and scientific updates, including data from the Surveillance HeartCare Outcomes Registry (SHORE) and other transplant studies. These releases describe how HeartCare, AlloSure Heart, and related molecular tests are evaluated as biomarkers for rejection risk, graft dysfunction, and treatment response in heart and kidney transplantation. Product‑focused news, such as the introduction of HistoMap Kidney and other molecular assays, further illustrates the company’s emphasis on transplant diagnostics.
Additional news items cover corporate and governance developments, such as leadership appointments, board changes, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and participation in investor conferences. Together, these updates offer investors, clinicians, and other stakeholders a consolidated view of CareDx’s activities in precision transplant medicine. For ongoing insight into CDNA, this page serves as a central source for company press releases and related disclosures.
CareDx announces a collaboration with Eledon Pharmaceuticals to assess the efficacy of Eledon's investigational drug, AT-1501, in preventing organ rejection in renal transplants using AlloSure technology. Eledon recently secured approval from Health Canada for human trials of AT-1501, which is expected to commence in Q4 2021 with interim data releases anticipated in late 2022. This partnership aims to leverage CareDx's innovative solutions to enhance patient outcomes in transplantation.
CareDx, Inc. (Nasdaq: CDNA) is set to report its third quarter 2021 financial results on October 28, 2021, after market close. A conference call will follow at 1:30 p.m. PT/4:30 p.m. ET. Interested parties can join by calling 877-705-6003 or 201-493-6725, referencing Conference ID: 13724010. CareDx specializes in precision medicine solutions for transplant patients, providing a range of testing services and digital healthcare tools aimed at improving patient outcomes.
CareDx, Inc. (Nasdaq: CDNA) announced the commercial launch of AlloSure Lung on October 12, 2021, in conjunction with the CHEST 2021 Meeting. This non-invasive testing solution aims to improve the management of high-risk lung transplant patients, who face significant survival challenges and the risk of Chronic Lung Allograft Dysfunction (CLAD). AlloSure Lung has already received coverage from several private payers and is supported by three clinical validation studies involving 155 patients. The product aims to meet an unmet need and enhance precision care for transplant patients.
CareDx, Inc. (CDNA) announced a multicenter study validating its solutions AlloMap and AlloSure for kidney transplantation, as published in Kidney360. This study, encompassing data from 14 top transplant centers, demonstrates that AlloMap can effectively differentiate between organ rejection and immune quiescence. The combination of AlloSure and AlloMap provides a comprehensive assessment, achieving a combined AUC of 0.894. CEO Reg Seeto emphasized the extended application of multimodality solutions in kidney care, reflecting CareDx's commitment to innovate in transplant medicine.
CareDx, Inc. (Nasdaq: CDNA) announced that a false advertising lawsuit against Natera will proceed to trial on October 25, 2021. In a separate matter, CareDx plans to appeal a recent court ruling that deemed three of its patents regarding non-invasive organ transplant monitoring ineligible. The company firmly believes that Natera and Eurofins Viracor are infringing on its patents, which are exclusively licensed from Stanford University. CareDx remains committed to enhancing transplant patient outcomes through innovative solutions.
CareDx, Inc. (CDNA) has announced its participation in the upcoming ASHI conference, featuring eight scientific abstracts related to AlloSeq Tx17 and AlloSeq HCT. The conference will take place from September 27-30, 2021, in Orlando, FL, showcasing innovations in transplant care. CEO Reg Seeto expressed pride in advancing transplant solutions, emphasizing the transformative role of AlloSeq HCT. Additionally, CareDx will host a lunch symposium discussing future innovations across the transplant journey.
CareDx Appoints Art Torres to Board of Directors
CareDx, Inc. (Nasdaq: CDNA) announced the appointment of Art Torres to its Board of Directors. Torres, a former California state senator and advocate for organ transplantation, brings extensive expertise in regenerative medicine and health equity. He is currently involved with several organizations, including the California Institute for Regenerative Medicine and One Legacy. His addition to the board is seen as a move to strengthen CareDx's commitment to improving support for transplant patients across diverse communities.
CareDx, a precision medicine company, announces its participation in two upcoming healthcare conferences. The first is the 2021 Wells Fargo Healthcare Conference on September 9, 2021, at 3:20 p.m. Eastern Time, with a live webcast available on the company's investor relations site. The second event is the H.C. Wainwright 23rd Annual Global Investment Conference, where CareDx will present on September 13, 2021, at 7:00 a.m. Eastern Time. CareDx specializes in solutions for transplant patients, offering services and products that enhance the pre- and post-transplant experience.
CareDx launches AlloSeq cfDNA Research Service and showcases leadership at ESOT 2021.
On August 26, 2021, CareDx, Inc. (Nasdaq: CDNA) announced its presence at the European Society of Organ Transplantation (ESOT) conference with six abstracts and an upcoming symposium. The AlloSeq cfDNA service detects donor-derived cfDNA in less than 24 hours and aims to expand research internationally from its Stockholm lab. The ESOT symposium on August 29 will highlight advanced strategies for allograft surveillance, featuring experts in the field.
CareDx, Inc. (Nasdaq: CDNA) reported second-quarter 2021 financial results with total revenue of $74.2 million, a 77% increase year-over-year. Testing services revenue reached $64.9 million, up from $36.3 million in Q2 2020. Notably, the company has generated approximately 37,400 AlloSure and AlloMap patient results this quarter. Despite a net loss of $1.9 million, an improvement from $6.6 million in the previous year, the company reported a non-GAAP net income of $5.9 million. CareDx raised its 2021 revenue guidance to a range of $280-$290 million.